Panel discussion featured at the International Society of Pain and Neuroscience (ISPN) Annual Meeting in London titled United to Conquer Pain Session Co-Moderator Doug Beall, M.D. underscored that disc chemistry is the critical biomarker for diagnosing the leading cause of chronic low back pain Nociscan® combines MR Spectroscopy and proprietary AI algorithms to deliver data-driven insights that inform treatment decisions to improve patient outcomes BROOMFIELD, Colo., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Aclari ...

Aclarion to Present at the LD Micro Main Event XIXPresentation on Monday, October 20, 2025 at 12:00 PM PTOctober 09, 2025 6:00 AM EDT | Source: LD MicroBroomfield, Colorado--(Newsfile Corp. - October 9, 2025) - Aclarion, Inc. (NASDAQ: ACON) (NASDAQ: ACONW) ("Aclarion" or the "Company"), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today that it wi ...

BROOMFIELD, Colo., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced its selection as a finalist in the Rising Star - Clinical Diagnostic Device category for the prestigious 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH. This recognition ...

Core Insights - Aclarion, Inc. is leveraging biomarkers and proprietary augmented intelligence algorithms to assist physicians in identifying chronic low back pain locations through its platform, Nociscan [1][3] - The company recently presented at LSI Europe '25, highlighting Nociscan's potential to transform the chronic low back pain market and enhance shareholder value [2] Company Overview - Aclarion is a healthcare technology company focused on chronic low back pain, utilizing Magnetic Resonance Spectroscopy (MRS) and proprietary signal processing techniques [3] - Nociscan is the first evidence-supported SaaS platform designed to noninvasively differentiate between painful and non-painful discs in the lumbar spine [3] Technology and Clinical Evidence - Nociscan converts MR spectroscopy signals into objective biomarker data, aiding physicians in creating personalized treatment plans [5] - The ongoing 300-patient CLARITY randomized clinical trial aims to demonstrate that Nociscan-guided surgical decision-making can improve surgical outcomes beyond the current 54% industry success rate, with interim results expected in Q2 2026 [5] Financial Position - Aclarion has recently strengthened its balance sheet, providing the necessary capital to achieve commercial and clinical milestones [5]

Core Insights - Aclarion, Inc. has initiated the CLARITY trial to evaluate the clinical and economic value of its Nociscan technology in spine surgery for chronic low back pain [1][3] Company Overview - Aclarion is a healthcare technology company focused on chronic low back pain, utilizing biomarkers and proprietary AI algorithms to assist physicians in identifying pain sources [1][4] - Nociscan is the first evidence-supported SaaS platform designed to noninvasively differentiate between painful and nonpainful lumbar discs [3][4] CLARITY Trial Details - The CLARITY trial is a prospective, randomized multi-center study involving 300 patients scheduled for surgical treatment of discogenic back pain [2][5] - The trial will randomize patients in a 1:1 ratio between surgeons blinded and unblinded to Nociscan results, with the primary endpoint being the change in back pain measured on a 100mm VAS scale at 12 months [2][5] - Initial patient enrollment has begun at the University of Miami Health System, with additional sites including Northwestern Medicine and Texas Back Institute [2][3] Market Context - Chronic low back pain affects an estimated 266 million people globally, representing a significant health challenge [3] - Aclarion aims for Nociscan to become the gold standard in identifying sources of low back pain through advanced diagnostic techniques [5][6]

Summary of SailPoint 2025 Conference Call Company Overview - **Company**: SailPoint (NasdaqGS: SAIL) - **Industry**: Identity Management and Security Core Competencies and Strategic Insights - SailPoint's core competency lies in its ability to manage identities in a "deep and wide" manner, mapping every identity across complex IT environments, which is challenging for enterprises [10][14] - The company manages approximately **125 million identities**, significantly more than competitors like Cyber Apollo, which manages about **8 million identities** [13] - The focus is on both human and non-human identities, recognizing that machine identities are increasingly becoming an attack vector [15][16] Innovation and Market Trends - The identity landscape is evolving, with a shift towards managing non-human identities, such as service accounts and software bots, which are now part of the attack vector [15][16] - There is a growing concern about the security of agents and machine identities, with the need for comprehensive mapping of the identity landscape [17][18] - The convergence of identity and security is essential for protecting enterprises from identity-centric attacks [18][40] Customer Insights and Adoption Challenges - Customers express excitement about deploying agent flows but are cautious due to concerns about potential security exposures [20][22] - There is a tension between the desire to adopt new technologies and the need for robust controls to manage risks associated with agents [22][25] - The concept of "orphan accounts" is highlighted, where non-human identities lack clear human ownership, posing security challenges [23] Financial Performance and Growth Metrics - SailPoint reported strong **Annual Recurring Revenue (ARR)** growth, particularly in SaaS, which now represents **60-70%** of total revenue [47][48] - The company anticipates continued growth, with a projected **30% ARR growth** by the end of the year, despite not yet capitalizing on new agentic offerings [48][50] Product Strategy and Market Positioning - SailPoint is launching an agentic identity security product, which is expected to be widely adopted due to customer demand for better management of identities [28][29] - The company emphasizes the importance of a comprehensive understanding of all identities and their access entitlements, moving beyond traditional privileged access management [36][40] - SailPoint aims to maintain a focus on large enterprises, identifying **14,000 target organizations** globally, with only **14% penetration** currently [68][70] Future Outlook - The company is positioned to innovate rapidly and deliver new offerings, with a focus on not overwhelming customers with too many features at once [54][55] - SailPoint's strategy includes leveraging its existing customer base while exploring new opportunities for growth within complex enterprise environments [70] Conclusion - SailPoint is navigating a rapidly changing identity management landscape, focusing on deep and wide identity management, addressing security concerns, and positioning itself for continued growth in the enterprise sector. The company is committed to enhancing its product offerings while ensuring robust security measures are in place to manage the complexities of modern identity management.

AI Development & Cultural Integration - The AI industry faces a paradigm shift where algorithms and ideologies are shaping content, necessitating human involvement to guide the narrative towards "augmented intelligence," which enhances human capabilities [2][4][5] - There is a global competition in AI development between the Western bloc (led by the US) and the Eastern bloc (led by China), highlighting the importance of participation to avoid being negatively impacted [6][9] - The US requires significant electricity investment (90 gigawatts, equivalent to approximately 90 nuclear power stations) to support AI energy demands, illustrating the scale of resources being directed towards AI [7] - The industry emphasizes the need to imbue AI with cultural norms to avoid bias and potential erasure of underrepresented groups, particularly concerning facial recognition and other AI applications [14][15] - The AI sector is rapidly advancing, with AI models surpassing human experts in certain disciplines, such as passing bar exams and SAT exams, indicating the potential for AI to outperform humans across various fields [18][19] Investment & Business Implications - Over $1 trillion has been invested in AI within the past year, including a $500 billion investment in data centers for AI infrastructure in the US, demonstrating the massive financial resources flowing into the AI sector [20][21] - Businesses are urged to integrate AI into their operations to remain competitive, as the majority of technology investment is currently directed towards AI [21] Call to Action - The industry calls for active participation in building AI platforms and developing tools that incorporate diverse cultural heritages, emphasizing that if local values are not embedded, they will be overlooked [26] - Educators are encouraged to raise the bar in education, assuming students are using AI and focusing on critical thinking and explanation rather than rote memorization [24][25] - Governments are urged to support local AI talent and innovation, fostering the development of AI systems that reflect local languages and cultural values [26][27][28]

Core Viewpoint - Aclarion, Inc. has appointed Greg Gould as the new Chief Financial Officer, bringing over 30 years of experience in public and private companies to drive growth and profitability [1][2][3] Company Overview - Aclarion is a healthcare technology company focused on chronic low back pain, utilizing biomarkers and proprietary AI algorithms to assist physicians in identifying pain sources [1][4] - The company's flagship product, Nociscan, is the first evidence-supported SaaS platform designed to noninvasively differentiate between painful and nonpainful discs in the lumbar spine [3][4] Leadership Transition - Greg Gould succeeds John Lorbiecki, who is retiring after establishing a strong financial foundation for Aclarion [1][2] - Gould has a proven track record, having raised over $450 million in public company debt and equity offerings and led multiple acquisitions [2][3] Market Opportunity - Chronic low back pain affects approximately 266 million people globally, presenting a significant market opportunity for Aclarion's innovative solutions [3] - Nociscan aims to improve surgical outcomes by objectively quantifying chemical biomarkers associated with disc pain [3][4] Technology and Innovation - Aclarion leverages Magnetic Resonance Spectroscopy (MRS) and proprietary signal processing techniques to optimize clinical treatments [4][5] - The Nociscan platform integrates with MRI machines to provide critical insights into the location of low back pain, enhancing treatment strategies for physicians [5]

Core Viewpoint - Aclarion, Inc. has reported a significant year-over-year growth in scan volume of 132% from Q2 2024 to Q2 2025, marking two consecutive quarters of growth for the first time, driven by new physician adoption and insurance coverage in the UK [1][6]. Group 1: Scan Volume Growth - The company has achieved a scan volume growth of 132% year-over-year from Q2 2024 to Q2 2025, indicating strong commercial traction [6]. - Aclarion expects continued quarter-over-quarter growth in scan volume through the remainder of 2025 and beyond, supported by new physician adoption and activation of commercial sites in the U.S. [2][6]. - Over 5.2 million people in the UK now have access to Nociscan through their insurance providers, which is expected to drive further volume increases [4][6]. Group 2: Key Catalysts - The first key catalyst for Aclarion is the growth of scan volume in the UK, where insurance approval for Nociscan has been secured, facilitating broader physician adoption [4][5]. - The second key catalyst is the CLARITY trial, which aims to demonstrate that using Nociscan in surgical planning can lead to better outcomes for patients with chronic low back pain, potentially securing widespread insurance coverage in the U.S. [5][6]. - The CLARITY trial is designed to validate Nociscan's ability to improve surgical outcomes, with internal interim results expected in Q2 2026 [6][8]. Group 3: Clinical Evidence and Publications - Aclarion's Nociscan has been shown to be more effective and less costly than provocative discography, saving $1,712 per patient and improving surgical success rates by 10% [9]. - The company is focused on building clinical evidence to support payment coverage for Nociscan, with a cost-effectiveness analysis published in a peer-reviewed journal [9]. - Aclarion continues to invest in real-world evidence development with customers in both the UK and U.S. [9]. Group 4: Customer and Market Strategy - The company remains selective in adding new customers outside the UK, focusing on strategic U.S. customers that prioritize real-world evidence development [9]. - Aclarion participated in six important industry conferences in the first half of 2025 to establish relevance and credibility among surgeons and spine societies [9]. Group 5: Intellectual Property and Funding - Aclarion holds 24 U.S. patents and is auditing its intellectual property portfolio to explore potential partnerships for optimizing shareholder value [9]. - The company raised nearly $15 million in net cash and eliminated all debt, ensuring it is adequately funded through Q3 2026 to execute its strategic objectives [9].

Core Insights - Aclarion, Inc. is participating in the State of Spine Surgery Think Tank to showcase its NOCISCAN platform, which utilizes biomarkers and AI to identify chronic low back pain [1][2] - Dr. Kris Radcliff will present the NOCISCAN platform, emphasizing its innovative approach to objectively identify discogenic pain [2] - The conference highlights the increasing interest in NOCISCAN's clinical and commercial value, as noted by Aclarion's Chief Strategy Officer [3] Company Overview - Aclarion is a healthcare technology company focused on chronic low back pain, leveraging Magnetic Resonance Spectroscopy (MRS) and AI algorithms [6] - NOCISCAN is the first evidence-supported SaaS platform designed to noninvasively distinguish between painful and nonpainful lumbar discs [4][6] - The platform quantifies chemical biomarkers associated with disc pain, providing critical insights when used alongside other diagnostic tools [4][6] Market Context - Chronic low back pain affects approximately 266 million people globally, representing a significant healthcare challenge [4] - The integration of NOCISCAN into clinical practice aims to develop personalized and effective surgical strategies for patients [2][3]